Home › Compare › PKCOF vs ABBV
PKCOF yields 1.34% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, PKCOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PKCOF + ABBV for your $10,000?
PARK24 Co., Ltd. operates and manages parking facilities in Japan and Internationally. The company operates through Parking Business Japan, Parking Business Overseas, and Mobility Business segments. Its services include hourly parking facilities; reserved parking and monthly parking services; parking facilities for non-passenger vehicles, such as large vehicles, motorcycles, and bicycles; and overseas parking facilities, including patrolled parking facilities, and pay and display parking services. The company also provides Times CAR RENTAL, a rent-a-car service; Times CAR, a membership based unattended rent-a-car service; Times Club membership service for drivers and Times Business service for corporate customers; The Times PAY, a payment service to the service industry, such as restaurants and retail outlets; membership-based road service; and insurance agency services comprising insurance consultation and financial planning services. PARK24 Co., Ltd. was founded in 1971 and is headquartered in Tokyo, Japan.
Full PKCOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.